EP1587955A4 - Markers for differential diagnosis and methods of use thereof - Google Patents

Markers for differential diagnosis and methods of use thereof

Info

Publication number
EP1587955A4
EP1587955A4 EP03810896A EP03810896A EP1587955A4 EP 1587955 A4 EP1587955 A4 EP 1587955A4 EP 03810896 A EP03810896 A EP 03810896A EP 03810896 A EP03810896 A EP 03810896A EP 1587955 A4 EP1587955 A4 EP 1587955A4
Authority
EP
European Patent Office
Prior art keywords
markers
methods
differential diagnosis
diagnosis
differential
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03810896A
Other languages
German (de)
French (fr)
Other versions
EP1587955A2 (en
Inventor
Kenneth F Buechler
Alan Maisel
Joseph Michael Anderberg
Paul H Mcpherson
Jeffrey R Dahlen
Howard J Kirchick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alere San Diego Inc
Original Assignee
Biosite Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/330,696 external-priority patent/US7713705B2/en
Priority claimed from US10/371,149 external-priority patent/US20030199000A1/en
Priority claimed from US10/603,891 external-priority patent/US20040253637A1/en
Priority claimed from US10/673,077 external-priority patent/US20040209307A1/en
Priority claimed from US10/714,078 external-priority patent/US20040219509A1/en
Application filed by Biosite Inc filed Critical Biosite Inc
Priority to EP07107064A priority Critical patent/EP1867734A1/en
Publication of EP1587955A2 publication Critical patent/EP1587955A2/en
Publication of EP1587955A4 publication Critical patent/EP1587955A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9123—Phosphotransferases in general with a nitrogenous group as acceptor (2.7.3), e.g. histidine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/974—Thrombin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP03810896A 2002-12-24 2003-12-23 Markers for differential diagnosis and methods of use thereof Withdrawn EP1587955A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07107064A EP1867734A1 (en) 2002-12-24 2003-12-23 Markers for differential diagnosis and methods of use thereof

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US43630102P 2002-12-24 2002-12-24
US436301P 2002-12-24
US10/330,696 US7713705B2 (en) 2002-12-24 2002-12-27 Markers for differential diagnosis and methods of use thereof
US330696 2002-12-27
US10/371,149 US20030199000A1 (en) 2001-08-20 2003-02-20 Diagnostic markers of stroke and cerebral injury and methods of use thereof
US371149 2003-02-20
US10/603,891 US20040253637A1 (en) 2001-04-13 2003-06-24 Markers for differential diagnosis and methods of use thereof
US603891 2003-06-24
US10/673,077 US20040209307A1 (en) 2001-08-20 2003-09-26 Diagnostic markers of stroke and cerebral injury and methods of use thereof
US673077 2003-09-26
US714078 2003-11-14
US10/714,078 US20040219509A1 (en) 2001-08-20 2003-11-14 Diagnostic markers of stroke and cerebral injury and methods of use thereof
PCT/US2003/041453 WO2004059293A2 (en) 2002-12-24 2003-12-23 Markers for differential diagnosis and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP07107064A Division EP1867734A1 (en) 2002-12-24 2003-12-23 Markers for differential diagnosis and methods of use thereof

Publications (2)

Publication Number Publication Date
EP1587955A2 EP1587955A2 (en) 2005-10-26
EP1587955A4 true EP1587955A4 (en) 2007-03-14

Family

ID=32686403

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03810896A Withdrawn EP1587955A4 (en) 2002-12-24 2003-12-23 Markers for differential diagnosis and methods of use thereof

Country Status (5)

Country Link
EP (1) EP1587955A4 (en)
JP (1) JP2006526140A (en)
AU (1) AU2003302340B8 (en)
CA (1) CA2511501A1 (en)
WO (1) WO2004059293A2 (en)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
MXPA03004105A (en) 2002-05-14 2004-10-15 Hoffmann La Roche Making a prognosis in cases of cardiac disease using a combination of markers.
BR0316223A (en) 2002-11-12 2005-10-04 Becton Dickinson Co Methods for determining sepsis status, predicting the onset of sepsis, and diagnosing systemic inflammatory response syndrome in an individual
MXPA05005031A (en) 2002-11-12 2005-11-17 Becton Dickinson Co Diagnosis of sepsis or sirs using biomarker profiles.
EP1519194A1 (en) * 2003-09-24 2005-03-30 Roche Diagnostics GmbH Use of gfap for identification of intracerebral hemorrhage
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
WO2005117969A2 (en) * 2004-04-26 2005-12-15 Centocor, Inc. Solution phase biopanning method using engineered decoy proteins
CA2574991C (en) 2004-07-23 2015-03-24 Aspenbio Pharma, Inc. Methods for diagnosis of appendicitis
US7659087B2 (en) 2004-07-23 2010-02-09 Aspenbio Pharma, Inc. Methods and devices for diagnosis of appendicitis
DE102004041659A1 (en) * 2004-08-27 2006-03-02 Institut Virion/Serion Gmbh Test device for the in vitro diagnosis of multi-analyte tests and their use
ITFI20040243A1 (en) * 2004-11-25 2005-02-25 Paola Romagnani DIAGNOSTIC METHOD FOR REJECTION OF TRANSPLANTED ORGAN
WO2006087373A1 (en) * 2005-02-17 2006-08-24 F. Hoffmann-La Roche Ag Use of nt-proanp/nt-probnp ratio for diagnosing cardiac dysfunctions
EP1869463A4 (en) 2005-04-15 2010-05-05 Becton Dickinson Co Diagnosis of sepsis
EP1888765A4 (en) * 2005-06-09 2008-11-05 Biosite Inc Methods and compositions for the diagnosis of venous thromboembolic disease
US20070099239A1 (en) * 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
US20070003981A1 (en) * 2005-06-29 2007-01-04 Rules-Based Medicine, Inc. Methods and kits for the diagnosis of acute coronary syndrome
EP1915613A4 (en) * 2005-07-08 2008-11-05 Philadelphia Health & Educatio Methods for monitoring neuroinflammatory destruction of neurons and for treating diseases having an inflammatory component related to phospholipase a2
WO2007007177A2 (en) * 2005-07-14 2007-01-18 Inverness Medical Switzerland Gmbh Mitochondrial markers of ischemia
DE102005034174A1 (en) * 2005-07-21 2007-02-08 B.R.A.H.M.S Ag CSF in vitro diagnostic procedure for dementia and neuroinflammatory diseases
DE102005036094A1 (en) * 2005-08-01 2007-02-08 B.R.A.H.M.S Ag In vitro method for the diagnosis of neurodegenerative diseases
JP2007082433A (en) * 2005-09-20 2007-04-05 Niigata Univ Malignant brain tumor marker gene and use of the same
WO2007041645A2 (en) * 2005-10-03 2007-04-12 Scios Inc. Oxidized human bnp
CA2633291A1 (en) * 2005-12-15 2007-07-12 Becton Dickinson And Company Diagnosis of sepsis
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
ES2550004T3 (en) 2006-04-04 2015-11-03 Singulex, Inc. High sensitivity system and troponin analysis methods
EP1845379A1 (en) * 2006-04-13 2007-10-17 F. Hoffmann-La Roche AG Means and methods for the differentiation of cardiac and pulmonary causes of shortness of breath
EP2021495A4 (en) 2006-05-09 2009-06-24 Musc Found For Res Dev Detecting diastolic heart failure by protease and protease inhibitor plasma profiling
DE102006023175A1 (en) * 2006-05-17 2007-11-22 B.R.A.H.M.S Aktiengesellschaft In vitro diagnostic and early diagnosis of neurodegenerative diseases
DE102006027818A1 (en) * 2006-06-16 2007-12-20 B.R.A.H.M.S. Aktiengesellschaft In vitro multiparameter determination method for the diagnosis and early diagnosis of neurodegenerative diseases
DE102006034142A1 (en) * 2006-07-24 2008-01-31 B.R.A.H.M.S. Aktiengesellschaft Method for controlling the therapy of heart failure patients by the in vitro determination of threshold levels of vasoactive peptides
EP1882947A1 (en) * 2006-07-28 2008-01-30 F. Hoffmann-La Roche AG Means and methods for the differentation of cardiac and pulmonary causes of acute shortness of breath
EP2047275B1 (en) * 2006-08-04 2011-06-01 Medizinische Hochschule Hannover Methods for assessing the risk of cardiac interventions based on gdf-15
AU2007284651B2 (en) * 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
EP1909206A1 (en) * 2006-09-11 2008-04-09 Roche Diagnostics GmbH Improvement of measuring range of a chromatographic rapid test
ES2334155T3 (en) * 2006-09-15 2010-03-05 F. Hoffmann-La Roche Ag BIOCHEMICAL MARKERS FOR ACUTE PULMONARY EMBOLISM.
US8449864B2 (en) 2006-10-20 2013-05-28 The Board Of Trustees Of The Leland Stanford Junior University Neurotensin as a marker and therapeutic target for sepsis
DE102006053442A1 (en) * 2006-11-12 2008-05-15 Brahms Aktiengesellschaft Diagnosis and risk stratification of infections and chronic diseases of the respiratory and lungs by means of proVasopressin, in particular copeptin or neurophysin II
US7842472B2 (en) 2006-11-14 2010-11-30 Alere International Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
EP2095106B1 (en) 2006-11-14 2013-03-20 Alere San Diego, Inc. Methods and compositions for diagnosis and prognosis of renal artery stenosis
SE532103C2 (en) 2006-12-12 2009-10-27 Knut Johansen Method for determining the health status of analytes in liquid samples
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
DE102007022367A1 (en) * 2007-05-07 2008-11-20 B.R.A.H.M.S Ag Method for the determination of amino-terminal pro-ANP in overweight patients
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
EP2019318A1 (en) * 2007-07-27 2009-01-28 Erasmus University Medical Center Rotterdam Protein markers for cardiovascular events
EP2020603A1 (en) * 2007-08-03 2009-02-04 BRAHMS Aktiengesellschaft Method for risk stratification in stable coronary artery disease
WO2009019230A2 (en) 2007-08-03 2009-02-12 Brahms Aktiengesellschaft Use of procalcitonin (pct) in risk stratification and prognosis of patients with a primary, non-infectious disease
US8431367B2 (en) 2007-09-14 2013-04-30 Predictive Biosciences Corporation Detection of nucleic acids and proteins
US20090075266A1 (en) * 2007-09-14 2009-03-19 Predictive Biosciences Corporation Multiple analyte diagnostic readout
EP2031397A1 (en) * 2007-08-30 2009-03-04 F. Hoffmann-La Roche AG Surfactant proteins B and D in differentiating the causes of shortness of breath
US8852893B2 (en) 2007-09-14 2014-10-07 Physicians Choice Laboratory Services, Llc Detection of nucleic acids and proteins
US7955822B2 (en) 2007-09-14 2011-06-07 Predictive Biosciences Corp. Detection of nucleic acids and proteins
WO2009083020A1 (en) 2007-12-28 2009-07-09 F. Hoffmann-La Roche Ag Assessment of physiological conditions
US8440418B2 (en) * 2008-11-18 2013-05-14 Ridge Diagnostics, Inc. Metabolic syndrome and HPA axis biomarkers for major depressive disorder
WO2009111595A2 (en) * 2008-03-04 2009-09-11 Ridge Diagnostics, Inc. Diagnosing and monitoring depression disorders based on multiple biomarker panels
WO2009114627A2 (en) * 2008-03-12 2009-09-17 Ridge Diagnostics, Inc. Inflammatory biomarkers for monitoring depression disorders
CA2718251A1 (en) * 2008-03-10 2009-09-17 Lineagen, Inc. Copd biomarker signatures
US7776522B2 (en) 2008-04-24 2010-08-17 Becton, Dickinson And Company Methods for diagnosing oncogenic human papillomavirus (HPV)
EP2318844A1 (en) * 2008-07-14 2011-05-11 Roche Diagnostics GmbH Multimarker panel for diagnosing, monitoring and selecting the therapy for patients with heart failure
ES2665245T3 (en) 2008-08-11 2018-04-25 Banyan Biomarkers, Inc. Biomarker detection process and neurological status test
EP2331964A1 (en) * 2008-08-13 2011-06-15 Roche Diagnostics GmbH D-dimer, troponin, nt-probnp for pulmonary embolism
EP2166358A1 (en) * 2008-09-17 2010-03-24 Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron Differential diagnostic biomarkers of stroke mimicking conditions and methods of use thereof
JP5219048B2 (en) * 2008-09-17 2013-06-26 独立行政法人農業・食品産業技術総合研究機構 Method for evaluating animal stress using anti-porcine interleukin-18 antibody
WO2010046136A1 (en) * 2008-10-24 2010-04-29 B.R.A.H.M.S. Ag Prognosis and risk assessment in stroke patients by determining the level of marker peptides
CA2755047C (en) 2009-03-11 2018-12-04 Promedior, Inc. Treatment methods for autoimmune disorders
EP2405928B1 (en) 2009-03-11 2016-11-02 Promedior Inc. Treatment and diagnostic methods for hypersensitive disorders
EA201101522A1 (en) 2009-05-11 2012-09-28 БЕРГ БАЙОСИСТЕМЗ, ЭлЭлСи METHODS OF TREATMENT OF DISEASES WITH THE USE OF EPIMETABOLIC SWITCH (COENZIM Q10)
UA110323C2 (en) 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
AU2010259022B2 (en) 2009-06-08 2016-05-12 Singulex, Inc. Highly sensitive biomarker panels
US9752191B2 (en) 2009-07-09 2017-09-05 The Scripps Research Institute Gene expression profiles associated with chronic allograft nephropathy
CN102472752B (en) 2009-08-28 2015-08-19 B.R.A.H.M.S有限公司 For the Procalcitonin of the prognosis of adverse events
ES2687469T3 (en) 2009-09-14 2018-10-25 Banyan Biomarkers, Inc. Autoantibody markers for the diagnosis of head trauma
CA2784889C (en) 2009-12-20 2018-06-19 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
SI2666872T1 (en) * 2010-02-05 2016-08-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20130096052A1 (en) * 2010-03-08 2013-04-18 B.R.A.H.M.S Gmbh Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with non-specific complaints
DK2550365T3 (en) 2010-03-22 2018-09-10 Stemina Biomarker Discovery Inc PREVENTION OF HUMAN DEVELOPMENTAL TOXICITY OF MEDICINAL PRODUCTS USING HUMAN STEM CELL-LIKE CELLS AND METABOLOMICS
WO2011139914A1 (en) * 2010-04-29 2011-11-10 Wisconsin Alumni Research Foundation Metabolic biomarkers of autism
AU2011249908A1 (en) 2010-05-06 2012-11-22 Singulex, Inc. Methods for diagnosing, staging, predicting risk for developing and identifying treatment responders for rheumatoid arthritis
EP2598887B1 (en) * 2010-07-28 2015-08-19 Abbott GmbH & Co. KG Method for detection of ischemic strokes
US20130338194A1 (en) * 2010-11-11 2013-12-19 Medical University Of South Carolina Predicting Atrial Fibrillation Recurrence by Protease and Protease Inhibitor Profiling
EP2492691A1 (en) 2011-02-22 2012-08-29 Institut de Recerca Hospital Universitari Vall d'Hebron Method of predicting the evolution of a patient suffering of a neurovascular disease
JP5976695B2 (en) 2011-03-11 2016-08-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ASC as a marker of chronic obstructive pulmonary disease (COPD)
EP2694463B8 (en) 2011-04-04 2019-10-09 Berg LLC Treating central nervous system tumors with coenzyme q10
US9541550B2 (en) 2011-05-09 2017-01-10 Sekisui Medical Co., Ltd. Method for immunologically measuring soluble LR11
RU2469332C1 (en) * 2011-10-12 2012-12-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения и социального развития Российской Федерации Differential diagnostic technique for bronchial asthma
BR122021026652B1 (en) 2011-10-17 2022-08-23 F. Hoffmann-La Roche Ag IN VITRO METHOD TO DIAGNOSE INTERMITTENT ATRIAL FIBRILLATION, USE OF A CARDIAC TROPONIN AND DEVICE TO DIAGNOSE INTERMITTENT ATRIAL FIBRILLATION
EP2786154B1 (en) * 2011-12-01 2017-11-01 Roche Diagnostics GmbH Nt-proanp and nt-probnp for the diagnosis of stroke
ES2734494T3 (en) 2011-12-08 2019-12-10 Astute Medical Inc Methods and uses for the diagnosis of kidney injury and kidney failure
EP2597465A1 (en) * 2012-06-26 2013-05-29 Roche Diagniostics GmbH TnT and H-FABP for diagnosis of cardiac damage in infection
US9414752B2 (en) 2012-11-09 2016-08-16 Elwha Llc Embolism deflector
WO2014072500A1 (en) 2012-11-09 2014-05-15 Roche Diagnostics Gmbh Tnt based diagnosis of paroxysmal atrial fibrillation
EP4105657A1 (en) 2013-01-17 2022-12-21 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2951318A4 (en) * 2013-02-01 2016-08-17 Univ West Virginia A biomarker algorithm for determining the time of stroke symptom onset and method
KR101494882B1 (en) 2013-02-21 2015-02-25 한국과학기술연구원 A composition for diagnosing acute myocardial infarction, a kit for diagnosing acute myocardial infarction comprising the composition, and a method for diagnosing acute myocardial infarction
WO2014168993A1 (en) 2013-04-08 2014-10-16 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
GB201309928D0 (en) * 2013-06-04 2013-07-17 Randox Lab Ltd Method
EP3022322A4 (en) 2013-07-17 2017-05-17 The Johns Hopkins University A multi-protein biomarker assay for brain injury detection and outcome
JP2016532115A (en) * 2013-08-30 2016-10-13 メタノミクス ゲーエムベーハー Means and methods for diagnosing heart failure in a subject
WO2015035094A1 (en) 2013-09-04 2015-03-12 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
FR3010187A1 (en) * 2013-09-05 2015-03-06 Ct Hospitalier Universitaire Rouen USE OF UROTENSIN II AND / OR URP AS MARKERS FOR THE DIAGNOSIS OF POST HSA VASOSPASM
WO2015179773A1 (en) 2014-05-22 2015-11-26 The Scripps Research Institute Tissue molecular signatures of kidney transplant rejections
US10794917B2 (en) 2013-09-20 2020-10-06 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain
AU2014351090A1 (en) * 2013-11-15 2016-06-16 Otago Innovation Limited Biomarker for cardiac disorders
US20150294081A1 (en) 2014-04-11 2015-10-15 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US9176113B1 (en) 2014-04-11 2015-11-03 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
EP3146076A4 (en) 2014-05-22 2018-05-09 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
US10443100B2 (en) 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
EP3146455A4 (en) 2014-05-22 2018-05-02 The Scripps Research Institute Molecular signatures for distinguishing liver transplant rejections or injuries
US11104951B2 (en) 2014-05-22 2021-08-31 The Scripps Research Institute Molecular signatures for distinguishing liver transplant rejections or injuries
WO2016065204A1 (en) * 2014-10-22 2016-04-28 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation Blood biomarkers for appendicitis and diagnostics methods using biomarkers
US10525020B2 (en) 2015-02-11 2020-01-07 Laboratory Corporation Of America Holdings Metabolic markers of attention deficit hyperactivity disorder
US10690681B2 (en) 2015-03-06 2020-06-23 Washington University Methods to detect myocardial injury and uses thereof
WO2017067821A1 (en) * 2015-10-22 2017-04-27 Universite Pierre Et Marie Curie (Paris 6) A method for determining presence or risk of hemostasis disorder
KR101801092B1 (en) 2016-01-28 2017-11-28 순천향대학교 산학협력단 Composition for Idiopathic pulmonary fibrosis prognosis and method of providing the information for the same
WO2017214203A1 (en) 2016-06-06 2017-12-14 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
CN108728525B (en) * 2017-04-19 2021-06-22 香港中文大学 Circulating microRNA biomarker for subarachnoid hemorrhage and application thereof
WO2018229051A1 (en) * 2017-06-13 2018-12-20 Roche Diagnostics Gmbh Fatty acid binding protein 3 for the assessment of atrial fibrillation (af)
EP3655545B1 (en) 2017-07-18 2023-10-18 The Research Foundation for The State University of New York Biomarkers for intracranial aneurysm
CN109975548B (en) * 2018-03-08 2020-08-07 中山大学 Application of IgG4 detection reagent in preparation of colorectal cancer diagnostic agent
WO2019189725A1 (en) * 2018-03-30 2019-10-03 国立研究開発法人国立精神・神経医療研究センター Neonatal hypoxic-ischemic encephalopathy severity determining method and prognosis predicting method
EP3553520A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Methods, uses and kits for monitoring or predicting response to periodontal disease treatment
EP3553518A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Periodontitis diagnostic methods, uses and kits
EP3553525A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Diagnostics of mild or advanced periodontitis
EP3553524A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Periodontitis diagnostic methods, uses and kits
JP7398226B2 (en) 2019-09-03 2023-12-14 浜松ホトニクス株式会社 Methods for assessing the risk of developing colorectal cancer
JPWO2021199792A1 (en) * 2020-04-02 2021-10-07
CN113791219B (en) * 2020-07-24 2022-08-02 首都医科大学附属北京天坛医院 Biomarker for acute ischemic stroke recurrence risk analysis and application thereof
CN113252910B (en) * 2021-06-29 2022-05-17 中国人民解放军军事科学院军事医学研究院 Application of TIMP3 in anxiety and depression diagnosis
CN115287346A (en) * 2022-05-26 2022-11-04 中山大学深圳研究院 Acute myocardial infarction early detection marker and detection kit
CN116059328A (en) * 2022-09-14 2023-05-05 深圳先进技术研究院 Application of TIMP3 recombinant protein in preparation of preparation for inhibiting hypertensive renal clear cell carcinoma

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996032648A1 (en) * 1995-04-11 1996-10-17 Spectral Diagnostics, Inc. Method and device for diagnosing and distinguishing chest pain in early onset thereof
WO2000052476A1 (en) * 1999-02-26 2000-09-08 Skye Pharmatech Incorported Method for diagnosing and distinguishing stroke
WO2002023191A1 (en) * 2000-09-12 2002-03-21 University Of Sydney Diagnostic assay
WO2002083913A1 (en) * 2001-04-13 2002-10-24 Biosite Diagnostics, Inc. Use of b-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
WO2002089657A2 (en) * 2001-05-04 2002-11-14 Biosite, Inc. Diagnostic markers of acute coronary syndromes and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599668A (en) * 1994-09-22 1997-02-04 Abbott Laboratories Light scattering optical waveguide method for detecting specific binding events
IL126544A (en) * 1996-04-25 2004-08-31 Genicon Sciences Inc Analyte assay using scattered-light detectable particles
EP1224463A2 (en) * 1999-10-08 2002-07-24 Superarray, Inc. Compositions and methods for detecting protein modification and enzymatic activity
EP1419388B1 (en) * 2001-08-20 2009-10-07 Biosite Incorporated Diagnostic markers of stroke and cerebral injury and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996032648A1 (en) * 1995-04-11 1996-10-17 Spectral Diagnostics, Inc. Method and device for diagnosing and distinguishing chest pain in early onset thereof
WO2000052476A1 (en) * 1999-02-26 2000-09-08 Skye Pharmatech Incorported Method for diagnosing and distinguishing stroke
WO2002023191A1 (en) * 2000-09-12 2002-03-21 University Of Sydney Diagnostic assay
WO2002083913A1 (en) * 2001-04-13 2002-10-24 Biosite Diagnostics, Inc. Use of b-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
WO2002089657A2 (en) * 2001-05-04 2002-11-14 Biosite, Inc. Diagnostic markers of acute coronary syndromes and methods of use thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AY HAKAN ET AL: "Creatine kinase-MB elevation after stroke is not cardiac in origin: comparison with troponin T levels.", STROKE; A JOURNAL OF CEREBRAL CIRCULATION. JAN 2002, vol. 33, no. 1, January 2002 (2002-01-01), pages 286 - 289, XP002413932, ISSN: 1524-4628 *
FUTTERMAN L G ET AL: "Novel markers in the acute coronary syndrome: BNP, IL-6, PAPP-A", AMERICAN JOURNAL OF CRITICAL CARE, THE ASSOCIATION, ALISO VIEJO, US, vol. 11, no. 2, March 2002 (2002-03-01), pages 168 - 172, XP008031012, ISSN: 1062-3264 *
LAMERS ET AL: "Cerebrospinal neuron-specific enolase, S-100 and myelin basic protein in neurological disorders", ACTA NEUROLOGICA SCANDINAVICA, MUNKSGAARD, COPENHAGEN, DK, vol. 92, 1995, pages 247 - 251, XP000910467, ISSN: 0001-6314 *
PERSSON L ET AL: "S-100 PROTEIN AND NEURON-SPECIFIC ENOLASE IN CEREBROSPINAL FLUID AND SERUM: MARKERS OF CELL DAMAGE IN HUMAN CENTRAL NERVOUS SYSTEM", STROKE, AMERICAN HEART ASSOCIATION, DALLAS TX, US, vol. 18, 1987, pages 911 - 918, XP000913410, ISSN: 0039-2499 *
QUINN DEBORAH A ET AL: "D-dimers in the diagnosis of pulmonary embolism", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 159, no. 5 PART 1, May 1999 (1999-05-01), pages 1445 - 1449, XP002413931, ISSN: 1073-449X *
SAGNELLA G A: "MEASUREMENT AND SIGNIFICANCE OF CIRCULATING NATRIURETIC PEPTIDES IN CARDIOVASCULAR DISEASE", CLINICAL SCIENCE, BIOCHEMICAL SOCIETY AND THE MEDICAL RESEARCH SOCIETY, LONDON,, GB, vol. 95, no. 5, November 1998 (1998-11-01), pages 519 - 529, XP009052621, ISSN: 0143-5221 *
SONEL A ET AL: "PROSPECTIVE STUDY CORRELATING FIBRINOPEPTIDE A, TROPONIN I, MYOGLOBIN, AND MYOSIN LIGHT CHAIN LEVELS WITH EARLY AND LATE ISCHEMIC EVENTS IN CONSECUTIVE PATIENTS PRESENTING TO THE EMERGENCY DEPARTMENT WITH CHEST PAIN", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, vol. 102, no. 10, 5 September 2000 (2000-09-05), pages 1107 - 1113, XP009053500, ISSN: 0009-7322 *
VILLACORTA HUMBERTO ET AL: "The role of B-type natriuretic peptide in the diagnosis of congestive heart failure in patients presenting to an emergency department with dyspnea.", ARQUIVOS BRASILEIROS DE CARDIOLOGIA. DEC 2002, vol. 79, no. 6, December 2002 (2002-12-01), pages 569 - 572 , 564, XP002413933, ISSN: 0066-782X *

Also Published As

Publication number Publication date
WO2004059293A2 (en) 2004-07-15
CA2511501A1 (en) 2004-07-15
AU2003302340B2 (en) 2008-08-21
JP2006526140A (en) 2006-11-16
AU2003302340B8 (en) 2008-09-11
AU2003302340A1 (en) 2004-07-22
WO2004059293A3 (en) 2005-03-31
EP1587955A2 (en) 2005-10-26

Similar Documents

Publication Publication Date Title
EP1587955A4 (en) Markers for differential diagnosis and methods of use thereof
IL172986A0 (en) Hairpin -labeled probes and methods of use
AU2003217870A8 (en) Pini-modulating compounds and methods of use thereof
EP1465615A4 (en) Tricyclic-bis-enone derivatives and methods of use thereof
AU2003213673A8 (en) Pin1-modulating compounds and methods of use thereof
HK1079789A1 (en) Vasculostatic agents and methods of use thereof
EP1701654A4 (en) Implantable biosensor and methods of use thereof
AU2003225669A1 (en) Pin1-modulating compounds and methods of use thereof
AU2003225668A1 (en) Pin1-modulating compounds and methods of use thereof
EP1603568A4 (en) Isoquinoline derivatives and methods of use thereof
AU2003253014A8 (en) Method for the diagnosis and differential diagnosis of neurological diseases
HK1084949A1 (en) Arylvinylazacycloalkane compounds and methods of preparation and use thereof
EP1639086A4 (en) Rna interferases and methods of use thereof
EP1638977A4 (en) Salinosporamides and methods for use thereof
AU2003265522A1 (en) FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
AU2003277164A8 (en) Imaging catheter with indicia and methods of use
AU2003285254A1 (en) Drilling fluid and methods of use thereof
EP1567515A4 (en) Novel lapachone compounds and methods of use thereof
EP1476150A4 (en) Carboxyfullerenes and methods of use thereof
EP1625111A4 (en) Thyronamine derivatives and analogs and methods of use thereof
EP1545287A4 (en) Vasoregulating compounds and methods of their use
PL2441767T3 (en) Salinosporamides and methods for use thereof
AU2003279800A8 (en) Sulfatases and methods of use thereof
EP1652934A4 (en) Improved method of amplifying atp and use thereof
IL169348A0 (en) Markers for differential diagnosis and methods of use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050725

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101ALI20070129BHEP

Ipc: C12Q 1/68 20060101AFI20050412BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20070209

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOSITE INCORPORATED

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ALERE SAN DIEGO, INC.

17Q First examination report despatched

Effective date: 20110413

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110824